Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Biomarkers
Cardiovascular Diseases
Cholesterol, LDL
Clinical Trials, Phase III as Topic
Down-Regulation
Dyslipidemias
Female
Humans
Lipoprotein(a)
Male
Middle Aged
Proprotein Convertase 9
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Serine Proteinase Inhibitors
Time Factors
Treatment Outcome

authors with profiles

Michael H. Davidson